Volume 133, Issue 21



May 23, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Dysfunctional osteoclasts in MF-associated osteosclerosis. See the article by Veletic et al.

Editing aberrant splice sites efficiently restores β-globin expression in β-thalassemia
In this Plenary Paper, the authors describe a promising novel therapeutic strategy using CRISPR-Cas to correct β-thalassemias resulting from aberrant donor or acceptor splice sites.

Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia
The investigators present a novel approach to the treatment of T-cell acute lymphoblastic leukemia using chimeric antigen receptor (CAR) T cells directed against CD1a.

NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML
The investigators report data indicating that the cell surface marker NCAM1 (neural cell adhesion molecule 1), also known as CD56 and expressed in approximately 15-20% of acute myeloid leukemia (AML) cases, promotes chemotherapy resistance and leukemia stem cell function.

Peripheral serotonin causes dengue virus–induced thrombocytopenia through 5HT2 receptors
The investigators identify a new mechanism of dengue virus–induced thrombocytopenia.

A cytosine-rich splice regulatory determinant enforces functional processing of the human α-globin gene transcript
The authors report a novel regulatory mechanism that ensures proper splicing of human α-globin pre–messenger RNA, without which a-thalassemia might be a more common disease.

Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy
The investigators explore the potential correlation between JAK inhibitor therapy and the risk of a subsequent lymphoma in patients with myeloproliferative neoplasms.

How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism
This How I Treat article offers guidance to the clinician struggling with anticoagulation issues in patients of older age.

Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL
This Blood Spotlight review highlights the mechanism of action of relapse-associated NT5C2 mutations in conferring resistance to 6-mercaptopurine/6-thioguanine chemotherapy in acute lymphoblastic leukemia (ALL).

View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.